There are 2789 resources available
Q&A and live discussion
Presenter: Christophe Massard
Session: Proffered Paper session - Developmental therapeutics
Resources:
Slides
Webcast
Invited Discussant 513O and 514O
Presenter: Elena Garralda
Session: Proffered Paper session - Developmental therapeutics
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Elena Garralda
Session: Proffered Paper session - Developmental therapeutics
Resources:
Slides
Webcast
Introduction by the chair
Presenter: Clara Montagut Viladot
Session: Do we need full molecular profile upfront in all CRC patients in daily practice?
Resources:
Slides
Webcast
Yes
Presenter: Sara Lonardi
Session: Do we need full molecular profile upfront in all CRC patients in daily practice?
Resources:
Slides
Webcast
No
Presenter: Rodrigo Dienstmann
Session: Do we need full molecular profile upfront in all CRC patients in daily practice?
Resources:
Slides
Webcast
Polling 2 (led by chair)
Presenter: Clara Montagut Viladot
Session: Do we need full molecular profile upfront in all CRC patients in daily practice?
Resources:
Slides
Webcast
Q&A
Presenter: Clara Montagut Viladot
Session: Do we need full molecular profile upfront in all CRC patients in daily practice?
Resources:
Slides
Webcast
LBA27 - Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study
Presenter: Thomas Powles
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Abstract
Slides
Webcast
651O - Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)
Presenter: Sarmad Sadeghi
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Abstract
Slides
Webcast